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Real-World Preliminary Experience With Responsive
Neurostimulation in Pediatric Epilepsy: A
Multicenter Retrospective Observational Study
BACKGROUND: Despite the well-documented utility of responsive neurostimulation (RNS,
NeuroPace) in adult epilepsy patients, literature on the use of RNS in children is limited.
OBJECTIVE: To determine the real-world efficacy and safety of RNS in pediatric epilepsy
patients.
METHODS: Patients with childhood-onset drug-resistant epilepsy treated with RNS were
retrospectively identified at 5 pediatric centers. Reduction of disabling seizures and complications were evaluated for children (<18 yr) and young adults (>18 yr) and compared with
prior literature pertaining to adult patients.
RESULTS: Of 35 patients identified, 17 were <18 yr at the time of RNS implantation,
including a 3-yr-old patient. Four patients (11%) had concurrent resection. Three complications, requiring additional surgical interventions, were noted in young adults (2 infections [6%] and 1 lead fracture [3%]). No complications were noted in children. Among the 32
patients with continued therapy, 2 (6%) achieved seizure freedom, 4 (13%) achieved ≥90%
seizure reduction, 13 (41%) had ≥50% reduction, 8 (25%) had <50% reduction, and 5 (16%)
experienced no improvement. The average follow-up duration was 1.7 yr (median 1.8 yr,
range 0.3-4.8 yr). There was no statistically significant difference for seizure reduction and
complications between children and young adults in our cohort or between our cohort
and the adult literature.
CONCLUSION: These preliminary data suggest that RNS is well tolerated and an effective
off-label surgical treatment of drug-resistant epilepsy in carefully selected pediatric
patients as young as 3 yr of age. Data regarding long-term efficacy and safety in children
will be critical to optimize patient selection.
KEY WORDS: Brain stimulation, Children, Closed-loop, Eloquent cortex, Multifocal epilepsy, Neuromodulation
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D

rug-resistant epilepsy (DRE) impacts
∼1/3 of patients who experience
partial-onset seizures.1 The responsive
neurostimulation system (RNS, NeuroPace,
Mountain View, California) is a cranially
implanted, closed-loop, brain-responsive stimulation system, currently approved by the U.S.
Food and Drug Administration for patients
ABBREVIATIONS: DRE, drug-resistant epilepsy;
RNS, responsive neurostimulation; SEEG, stereoelectroencephalography; VNS, vagus nerve
stimulation
Neurosurgery Speaks! Audio abstracts available for this
article at www.neurosurgery-online.com.
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with DRE despite an adequate trial of ≥2
antiepileptic medications who are ≥18 yr of
age and have 1 or 2 unresectable seizure foci.
The system has 2 ports allowing connection
of two 4-contact leads (depth and/or subdural
cortical strip leads). Additional leads may be
implanted and left unconnected for future use.
The system continues to sense electrocorticographic activities and can be programmed to
deliver stimulation customized along multiple
parameters in response to specific electrocorticographic patterns. Prior studies demonstrated the
benefits and safety of RNS in patients of age 18
to 70 yr.2-6
Despite well-documented utility in adult
epilepsy patients, literature on the use of RNS
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METHODS
Study Design and Setting
This study was a multicenter retrospective cohort study across 5
academic pediatric epilepsy centers in the United States. The study
centers include (1) UCLA Mattel Children’s Hospital in Los Angeles,
California; (2) Primary Children’s Hospital in Salt Lake City, Utah;
(3) Lucille Packard Children’s Hospital Stanford in Palo Alto, California;
(4) Nicklaus Children’s Hospital in Miami, Florida; and (5) Children’s
Hospital Colorado in Aurora, Colorado. This study was approved by the
institutional review board at each participating center with a waiver of
informed consent.

Participants and Perioperative Management
We included consecutive patients who underwent RNS (NeuroPace)
implantation at the participating pediatric epilepsy centers. All patients
with a history of childhood-onset DRE who underwent RNS implantation before April 2020 were identified. Patients who had a history
of prior epilepsy surgery and/or who had concurrent partial resection
of a presumed epileptogenic zone were considered eligible for the
study. Patients who had 1 functional/connected RNS lead targeting
the thalamus were also considered eligible, but those who had both
functional/connected leads targeting the thalamus (ie, an RNS system
used in place of a deep brain stimulation device) were excluded. All
identified patients underwent RNS implantation after a standard presurgical evaluation and discussion in a multidisciplinary epilepsy conference.
Despite relatively minor institutional differences (eg, duration of
perioperative antibiotics), all patients in this study, both children (<18
yr) and young adults (>18 yr), were managed similarly during the perioperative period at each participating center, without any differences in
the technical aspects of RNS implantation (eg, 4 centers delayed RNS
implantation following stereoelectroencephalography [SEEG] evaluation; 3 centers used intraoperative Bacitracin irrigation and 2 centers
used intraoperative Vancomycin powder; all centers implanted the entire
RNS system [leads and generator] during 1 surgery). In general, no
special precautions (other than avoiding contact sports) were taken
postoperatively to reduce the risk of device damages.
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Variables and Outcomes
The following clinical variables were collected: clinical history, results
of presurgical workups, surgical details, complications (ie, procedure- or
device-related adverse events resulting from RNS implantation or use and
resulting in previously unplanned surgery), latest stimulation parameters,
side effects from RNS therapy, and seizure outcomes at the time of last
follow-up.
Two complementary methods were used to estimate seizure outcome:
estimated seizure reduction and categorical outcome. Baseline seizure
frequency and seizure outcome were defined as the number of disabling
seizures occurring in the 3-mo period before RNS intervention or in the
3-mo period before most recent follow-up, respectively (% reduction
= [# seizures before RNS implantation – # seizures after RNS implantation]/# seizures before RNS implantation ∗ 100). Each patient was
placed into 1 of 5 categorical outcomes: (1) free of disabling seizures;
(2) ≥90% reduction of disabling seizures; (3) ≥50% but
<90% reduction of disabling seizures; (4) <50% but some noticeable
reduction of disabling seizures; or (5) no improvement. Collectively,
“responders” were defined as patients with ≥50% reduction of disabling
seizures (categories 1-3), and “super-responders” as those with ≥90%
reduction of disabling seizures (categories 1 and 2). Additionally,
qualitative improvement in disabling seizures was noted.

Study Size
Given the rarity of RNS use in pediatric patients, we aimed to recruit
as many participants as possible from the participating centers. No
sample size calculation was performed.

Statistical Methods
The baseline characteristics of the participants were summarized using
descriptive statistics. Continuous variables were reported using means,
standard deviations, and ranges. Categorical variables were presented
using frequencies and percentages. Participants were stratified into 1
of the 2 cohorts according to age at the time of RNS implantation
(<18 yr and ≥18 yr) and compared accordingly. The Wilcoxon-MannWhitney test was used to assess differences in continuous variables.
The Fisher exact test was used to identify significant differences in
binomial categorical variables, while the chi-squared test was used for
the assessment of multinomial categorical variables. When comparing
the results with published literature, an unpaired t-test was used for
continuous variables and the Fisher exact was used for categorical
variables. A 2-sided P-value ≤ .05 was used as the threshold for statistical significance in all analyses. All statistical analyses were performed in
RStudio (RStudio Inc., Version 1.2.1335).

RESULTS
Participants and Descriptive Data
A total of 35 patients (mean age at RNS (NeuroPace) implant
16.6 ± 5 yr, range 3-25 yr; 34% female) were included in the
study (Figure 1, Table 1), including 17 patients <18 yr at the
time of RNS implantation (mean age 12.6 ± 3.9 yr, range 317 yr; 24% female) (Figure 2). The average duration of epilepsy
before RNS implantation was 9.9 ± 5.4 yr. Previous interventions included focal resection in 10 patients (28.6%) and vagus
nerve stimulation (VNS) therapy in 4 patients (11.4%), with the
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(NeuroPace) in children is limited.7-9 We undertook a multicenter study to retrospectively assess the efficacy and safety of
RNS at multiple pediatric epilepsy centers in a diverse, real-world
pediatric population.

RESPONSIVE NEUROSTIMULATION IN PEDIATRIC EPILEPSY

low rate of prior VNS therapy partially reflecting the focal (up to
2) nature of epilepsy in these patients (thus candidates for RNS
therapy).
All patients underwent invasive intracranial recordings before
RNS implantation: SEEG alone in 15 patients (42.9%),
craniotomy for placements of subdural cortical electrodes
with/without depth electrodes in 14 patients (40.0%), and both
methods in separate monitoring sessions in 6 patients (17.1%).
Eighteen patients (51.4%) had an RNS system implanted at
completion of the invasive recording, typically concurrent with
the reoperative craniotomy and electrode removal.
The most common indication for use of RNS (Table 1) was
an epileptogenic zone involving primary motor/sensory area (13
patients, 37.1%). Some patients had multiple indications. The
number of electrodes placed ranged from 2 to 4 (mean 2.7,
median 2); bilateral electrodes were placed in 7 cases (20.0%).
The average follow-up duration was 1.7 ± 1.0 yr (0.3-4.8 yr).
There were no significant differences in the evaluated variables
between the age subgroups.
Adverse Events and Complications
There were 9 adverse events and complications (Table 2).
Five patients experienced side effects related to stimulation (see
Table 2 for details). Two patients required surgical wound
washout and removal of the RNS system because of infection.
Lead fracture occurred in 2 patients (5.7%): in 1 patient, ≥50%
seizure reduction was achieved initially, but lead fracture occurred
∼2 yr after surgery, presumably as a result of a fall unrelated
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to seizures. Because of progressively diminishing verbal memory,
removal of the RNS and left hippocampectomy were eventually
performed. The second patient with a lead fracture achieved
seizure freedom; high impedance was noted in the less active
lead 7 mo after the implant, without requiring a surgical intervention. There were no statistically significant differences in the
incidence of adverse events and complications between the age
subgroups. No patients under 18 yr of age experienced complications requiring additional surgical interventions.
Outcome Data
One patient who underwent right frontal resection at the
time of RNS placement with 2 strip electrodes placed over
the ipsilateral primary motor area achieved seizure freedom
without having the RNS system turned on. This patient and 2
patients explanted due to device infection were excluded from
the outcome analysis (Table 3). Of the 32 patients (91.4%), 2
patients (6%) achieved freedom from disabling seizures, 4 patients
(13%) achieved ≥90% freedom, 13 patients (41%) had ≥50%
freedom, 8 patients (25%) had <50% reduction of disabling
seizures, and 5 patients (16%) experienced no improvement. For
the subgroup of 17 patients under the age of 18 yr, 1 patient
(6%) achieved freedom from disabling seizures, 3 patients (18%)
achieved ≥90% freedom, 6 patients (35%) had ≥50% freedom,
3 patients (18%) had <50% reduction of disabling seizures, and
4 patients (24%) experienced no improvement. Many patients
and/or family members noted qualitative improvement in the
nature of their seizure events (decreased intensity or decreased

VOLUME 0 | NUMBER 0 | 2021 | 3

Downloaded from https://academic.oup.com/neurosurgery/advance-article/doi/10.1093/neuros/nyab343/6370896 by Henry Ford Hospital user on 26 October 2021

FIGURE 1. Patient flow chart. A total of 35 patients underwent RNS (NeuroPace) implantation in this
series. The outcome of RNS therapy was assessed for 32 patients who received RNS therapy, excluding 2
patients with wound infection requiring RNS removal and 1 patient who achieved seizure freedom without
RNS therapy. The outcome for a patient who initially received RNS therapy but subsequently underwent
RNS removal and hippocampectomy due to a lead fracture was assessed at the time of the most recent followup before the RNS removal.

NAGAHAMA ET AL

TABLE 1. Baseline and Demographic Characteristics
All patients (n = 35)

Patients <18 yr (n = 17)

Patients ≥ 18 yr (n = 18)

P-value

Age at time of RNS (yr)
Age at seizure onset (yr)
Epilepsy duration before RNS (yr)
Female
Patient weight at time of RNS (kg)
Epilepsy syndrome
Multifocal
Focal
Generalized
Known genetic abnormality, name (n)b
CHRNB2
Lennox-Gastaut
Pierre-Robin
RELN + CACNA1H
Hx of infantile spams
AEDs trialed
Previously trialed and discontinued
In use at time of RNS
Structural abnormality on MRIc
Cortical dysplasia
Mesial temporal sclerosis
Gliosis
Focus of T2 signal change
Other
Other phase I workups performed
vEEG
PET
MEG
Concordance if ≥ 2 used
Prior therapeutic surgery
Focal resection
Vagus nerve stimulation
Corpus callosotomy
Other
Phase II monitoring
SEEG
Craniotomy (cortical with/without
depth electrodes)
Both
Important technical differences
Resection at the time of RNS
RNS at the time of SEEG and/or
subdural electrode removal
Days of IC monitoring just prior to
RNSd
Indication for RNS
Bitemporal
Multifocal
Primary motor/sensory
Language
Preserved memory
Difficult-to-access region (eg, insula)
Total RNS leads (per patient):
implanted/connected
Depth implanted

16.6 ± 5 (3-25)
6.7 ± 4.5 (0.5-18)
9.9 ± 5.4 (1-20)
12 (34%)
59.8 ± 19.4 (17.5-102.9)

12.6 ± 3.9 (3-17)
5.7 ± 3.2 (2-13)
7.0 ± 4.0 (1-13.5)
4 (24%)
53.8 ± 25.4 (17.5-102.9)

20.3 ± 2 (18-25)
7.6 ± 5.4 (0.5-18)
12.7 ± 5.3 (4-20)
8 (44%)
65.4 ± 8.6 (52.2-87.7)

<.001a
.371
.003a
.289
.049a
.486

10 (29%)
23 (66%)
1 (3%)

6 (35%)
11 (65%)
0

4 (22%)
12 (67%)
1 (6%)

1 (2.9%)
1 (2.9%)
1 (2.9%)
1 (2.9%)
2 (6%)

1 (5.9%)
0
1 (5.9%)
0
0

0
1 (5.6%)
0
1 (5.6%)
2 (11%)

4.4 ± 2.9 (1-11)
2.9 ± 1.2 (1-6)

4.1 ± 2.7 (1-10)
2.7 ± 1.4 (1-6)

4.7 ± 3.2 (1-11)
3.1 ± 1.1 (1-5)

6 (17%)
3 (9%)
2 (6%)
5 (14%)
1 (3%)

4 (24%)
1 (6%)
1 (6%)
2 (12%)
0

2 (11%)
2 (11%)
1 (6%)
3 (17%)
1 (6%)

35 (100%)
30 (86%)
10 (29%)
22 (67%)

17 (100%)
15 (88%)
5 (29%)
9 (56%)

18 (100%)
15 (83%)
5 (28%)
13 (77%)

1.000
1.000
1.000
.282

10 (29%)
4 (11%)
1 (3%)
1 (3%)

2 (12%)
0
0
0

8 (44%)
4 (22%)
1 (6%)
1 (6%)

.059
.104
1.000
1.000

15 (43%)
14 (40%)

9 (53%)
4 (24%)

6 (33%)
10 (55%)

.314
.086

6 (17%)

4 (24%)

2 (11%)

.402

4 (11%)
18 (51%)

0
7 (41%)

4 (22%)
11 (61%)

.104
.318

6.4 ± 3.1 (3-14)

7.3 ± 3.9 (4-14)

5.8 ± 2.5 (3-11)

.513

5 (14%)
9 (26%)
13 (37%)
4 (11%)
7 (20%)
1 (3%)
2.7 ± 0.9 (2-4)/2 ± 0

2 (12%)
5 (29%)
5 (29%)
2 (12%)
4 (24%)
0
2.5 ± 0.8 (2-4)/2 ± 0

3 (17%)
4 (22%)
8 (44%)
2 (11%)
3 (17%)
1 (6%)
2.8 ± 0.9 (2-4)/2 ± 0

1.000
.711
.489
1.000
.691
1.000
.220/1.000

1.2 ± 1.1 (0-4)

1.3 ± 1.1 (0-4)

1.2 ± 1.2 (0-4)

.726
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.405

.486
.581
.111
.708
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TABLE 1. Continued

Depth connected
Strip implanted
Strip connected
Unilateral (vs bilateral)
Follow-up duration (yr)

All patients (n = 35)

Patients <18 yr (n = 17)

Patients ≥ 18 yr (n = 18)

P-value

1.1 ± 0.9 (0-2)
1.4 ± 1.4 (0-4)
0.9 ± 0.9 (0-1)
28 (80%)
1.7 ± 1.0 (0.3-4.8)

1.1 ± 0.9 (0-2)
1.2 ± 1.2 (0-4)
0.9 ± 0.9 (0-2)
14 (82%)
1.3 ± 0.7 (0.3-2.6)

1.1 ± 0.9 (0-2)
1.7 ± 1.6 (0-4)
0.9 ± 0.9 (0-2)
14 (78%)
2.0 ± 1.2 (0.3-4.8)

1.000
.400
1.000
1.000
.133

RNS, responsive neurostimulation; IC, intracranial monitoring; vEEG, video electroencephalography; MEG, magneto encephalography; PET, positron emission tomography; SEEG,
stereo-EEG; AED, antiepileptic drug.
a
Statistically significant with P-value ≤ 0.05.
b
Genetic testing was not performed on all patients; however, 4 patients were found to harbor single nucleotide polymorphisms or demonstrate a clinical syndrome associated with
epilepsy.
c
Structural abnormalities noted on MRI did not necessarily localize to the suspected epileptogenic cortex and did not include MRI changes that were postsurgical in nature. “Other”
refers to one patient with a convexity arachnoid cyst remote from the suspected region of seizure onset.
d
The number of days for intracranial monitoring prior to RNS implantation surgery is reported as a possible risk factor for infection. This refers to cases in which RNS was implanted at
the time of removal of intracranial electrodes after completion of phase II intracranial monitoring in the same operation. There was a trend toward increased utilization of craniotomy
during phase II monitoring in young adults (55%) vs children (24%). Subsequently, to avoid performing multiple craniotomies, RNS implantation at the time of electrode removal
was performed more often in young adults (61%) vs children (41%).
Data reported as mean ± SD (min–max) or n (%).

FIGURE 2. A-C, RNS (NeuroPace) placement in a 3-yr-old patient with multifocal seizure foci. The patient, who had been noted to have seizure foci
involving the right insula and left inferior frontal area, underwent uncomplicated RNS placement with 2 depth leads targeting those areas. A, Lateral and B,
anterior-posterior postoperative X-ray films show appropriate placement of the RNS device. C, Coronal postoperative CT demonstrated appropriate placement
of the RNS neurostimulator device along the contour of the left parietal area.

duration). There was no significant difference in quantitative
and qualitative effectiveness of RNS therapy between the age
subgroups (Table 3).
Comparison With Previous Studies
The baseline characteristics, adverse events and complications,
and seizure outcomes from this series were compared with the
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results from the landmark randomized trial performed on an
adult population by Heck et al2 (Table 4). There were statistically
significant differences in the variables expected based on the age
differences (eg, age at RNS implantation, epilepsy duration), as
well as the percentage of the patients who underwent intracranial
recordings before RNS implantation (P < .001). However, there
were no statistically significant differences in the risks of adverse
events and complications or in seizure outcome.
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TABLE 2. Adverse Events and Complications That Resulted from Implantation and/or Use of RNS (NeuroPace) System
Patients <18 yr (n = 17)

Patients ≥ 18 yr (n = 18)

P-value

5 (14%)

3 (18%)

2 (11%)

.658

1 (3%)

1 (6%)

0

.486

2 (6%)
0

0
0

2 (11%)
0

.486
1.000

1 (3%)
0

0
0

1 (6%)
0

1.000
1.000

RNS, responsive neurostimulation.
a
One patient experienced intermittent, at times painful muscle spasms and dysesthetic pain in the right upper extremity. Two patients could not tolerate higher current on depth
electrode stimulation without a painful sensation. One patient experienced tingle and vibration to right foot, a lower-extremity burning sensation, and occasional shock-like
sensation in the right arm and leg. One patient experienced left eye twitching.
b
Both cases of infection required hardware removal with antibiotic treatment. No cases of infection were treated with antibiotics alone without hardware removal. Both these 2
patients with infection requiring hardware removal were ≥ 18 yr old. Both patients underwent craniotomy for electrode placement. One of these patients underwent 9 d and the
other 4 d of intracranial monitoring just prior to RNS implantation.
c
There was one instance of lead fracture 2 yr after implantation likely secondary to head trauma from an accidental mechanical fall, not related to seizures. Since the time of
implantation, the patient’s verbal memory had declined, so the decision was made to remove the RNS system and perform a hippocampectomy.

TABLE 3. Outcomes for Patients Comparing a 3-Month Follow-up Period After RNS (Neuropace) With a 3-Month Presurgical Period
Description
Estimated % reduction in seizures
Qualitative outcome
Decreased intensity
Decreased duration
Less frequent
Lower incidence of secondary generalization
Seizure outcome categorya
Free of disabling seizures
≥90% reduction
≥50% but < 90% reduction
<50% but some reduction
No improvement
Stimulation parametersb
Current (mA)
Frequency (Hz)
Pulse width (μS)
Burst duration (mS)
Charge density (μC/cm2 )

All patients (n = 32)

Patients <18 yr (n = 17)

Patients ≥ 18 yr (n = 15)

P-value

54.7 ± 33.4 (0-100)

54.4 ± 36.1 (0-100)

55.2 ± 31.2 (0-86)

.894

16 (50%)
13 (41%)
20 (63%)
10 (31%)

11 (65%)
9 (53%)
9 (53%)
5 (29%)

7 (47%)
6 (40%)
12 (80%)
6 (40%)

.477
.502
.148
.712

2 (6%)
4 (13%)
13 (41%)
8 (25%)
5 (16%)

1 (6%)
3 (18%)
6 (35%)
3 (18%)
4 (24%)

1 (7%)
1 (7%)
7 (47%)
5 (33%)
1 (7%)

1.000
.603
.720
.424
.338

4 ± 2.1 (0.5-7)
189.7 ± 31.7 (75-200)
160 ± 0
100 ± 0
2.2 ± 0.9 (0.5-3.5)

3.7 ± 2.2 (0.5-7.0)
185.7 ± 38.7 (75-200)
160 ± 0
100 ± 0
2 ± 1 (0.5-3.5)

4.4±2 (1-7)
194 ± 20.8 (125-200)
160 ± 0
100 ± 0
2.4 ± 0.8 (1-3.5)

.359
.648
1.000
1.000
.214

RNS, responsive neurostimulation.
a
This categorical outcome is determined by the treating physician for each patient even if the information available is not sufficient to count the recent and baseline seizures over
3 mo and calculate % seizure reduction.
b
Stimulation parameters are taken from the most recent clinical visit. Complete data for stimulation parameter were available for 29 out of 32 patients.
Mean ± SD (min–max) or n (%).

DISCUSSION
Key Results
The efficacy and safety of RNS (NeuroPace) have been well
described in adults (≥18 yr),2-5 but the literature describing the
safety and efficacy in children is limited.7-9 With the growing
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use of RNS in pediatric centers, there is a critical need to
understand the efficacy and safety of RNS therapy in children.
Our collective preliminary experience suggests that RNS is
effective in reducing the number of disabling seizures in the
majority of pediatric patients, is well tolerated, and can be
performed with acceptable safety. The efficacy and safety profiles
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Adverse events
Bothersome side effects related to
stimulationa
Lead fracture not requiring revision
Complications (events resulting in
unplanned surgical intervention)
Infectionb
Hematoma evacuation
Hardware revision
Hardware failurec
Lead revision due to misplacement

All patients (n = 35)

RESPONSIVE NEUROSTIMULATION IN PEDIATRIC EPILEPSY

TABLE 4. Comparison With Published Literature
This cohort

P-value

97
34.0 ± 11.5 (18-60)
20.0 ± 11.2 (2-57)
47 (48%)
2.8 ± 1.3 (1-8)
34 (35%)
63 (65%)

35
16.6 ± 5 (3-25)
6.7 ± 4.5 (0.5-18)
12 (34%)
2.9 ± 1.2 (1-6)
13 (37%)
35 (100%)

<.001a
<.001a
.169
.691
.839
<.001a

191
7 (4%)
7 (4%)
5 (3%)

35
2 (6%)
1 (3%)
2 (6%)

.633
1.000
.297

183
16 (9%)
99 (54%)
150 (82%)

32
2 (6%)
19 (59%)
25 (78%)

1.000
.701
.624

RNS, responsive neurostimulation.
a
Statistically significant with P-value ≤ .05.
Data reported as mean ± SD (min-max) or n (%).

noted in this study are comparable with those in the adult
literature.
Interpretation
With respect to the efficacy of RNS, the number of
disabling seizures was reduced in 27 of 32 patients (84.4%). In
particular, 19 of 32 patients (59.4%) achieved ≥50% reduction
(“responders”), including 6 patients (18.8%) who achieved
≥90% reduction (“super-responders”). For the subgroup of the
17 patients under the age of 18 yr, the responder rate and
super-responder rate were 58.8% and 23.5%, respectively. The
responder rate in this pediatric series with the median follow-up
duration of 1.8 yr is comparable with the results from the initial
randomized study of the RNS system in adults (ie, 44% at 1 yr
and 55% at 2 yr).2 The responder rate was not as high as the rates
reported in a more recent multicenter adult RNS series (ie, 66% at
1 yr and 77% at 2 yr),10 which could be at least partially explained
by limited experience with pediatric RNS, the small number
of patients included in the current study, and the diversity and
complexity unique to pediatric epilepsy (eg, all the patients in this
study required intracranial recordings, more extratemporal cases,
diverse pathologies). Given the known improvement of seizure
control over time with programming optimization and likely
neuromodulatory effects of long-term stimulation therapy,2,5,10
seizure control may continue to improve in our cohort with longer
follow-ups.
The rate of adverse events and complications in this series was
comparable with those reported in the prior adult RNS studies.
Three patients experienced clinically significant complications
(2 patients with infection and 1 patient with a lead fracture)
NEUROSURGERY

requiring surgical interventions. These 3 patients were all ≥18
yr at the time of RNS implant. None of the patients under 18 yr
of age experienced complications.
Complexity and Diversity of Pediatric RNS
In prior adult studies, 59% to 82% of the patients underwent
preoperative workups with intracranial recording,2,3,5,10 whereas
all the patients in our series underwent intracranial recording.
However, the type of intracranial recording used was variable
across the institutions. In addition, the number of RNS leads
placed was variable across the institutions, with some using 2 leads
only and the others using a variable number of leads between 2
and 4. The strength of a multi-institutional cohort design is that
the flexibility in clinician treatment strategies and variability in
clinical pathologies are reflected, better approximating the true
diversity seen in a pediatric population and increasing the generalizability of these results.
Unique Considerations in Pediatric RNS
As we expand use of RNS to the pediatric population, it
is critical to consider how to determine the lower age limit.
Considering this procedure invariably involves a craniectomy
for device implantation, the benefits and potential harm based
on the variable skull development in individual patients should
be considered. Children experience rapid skull growth within
the first 2 yr and reach ∼90% of the adult skull volume by
7 yr.11 There were 2 patients under 7 yr at the time of RNS
implantation included in this study. The youngest was 3 yr of
age at the time of RNS implantation, which is the youngest
reported patient to undergo RNS implantation (personal
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Baseline characteristics
Number of patients included
Age in years at time of RNS
Epilepsy duration in years before RNS
Female
AEDs at time of RNS
Prior therapeutic surgery
Prior EEG monitoring with intracranial electrodes
Adverse events
Number of patients included
Infection
Device lead revision
Device lead damage
Outcomes
Number of patients included
Free of disabling seizures
50% or greater reduction of disabling seizures (“responders”)
Some reduction of disabling seizures

Heck et al cohort

NAGAHAMA ET AL

Limitations
The limitations of this current study include those typical
of a retrospective observational study (ie, no randomization, no
control arm, no blinded evaluation, no systematic prospective
documentation of seizure events). The follow-up duration was
also limited in some patients, likely underestimating the effectiveness of RNS therapy in those patients.

CONCLUSION
This retrospective multicenter study suggests that the use
of RNS (NeuroPace) in the pediatric population is safe and
feasible with more than half the patients in this series achieving
≥50% reduction of disabling seizures. The preliminary data
suggest efficacy compatible with the adult RNS experience. A
future long-term prospective study on pediatric RNS use will be
critical to further assess the efficacy and safety of RNS use in
children and to examine issues unique to children, such as skull
immaturity/growth and more surgeries for battery replacement
over longer life expectancies.
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communication, NeuroPace). In cases of severe, refractory
epilepsy, the benefits of neuromodulation may outweigh the
potential harm in patients who are <7 yr old. Theoretically, once
skull growth nears maturity, there is likely less concern for future
complications. Open sutures in infants would be a contraindication due to the small head size and the difficulty in securing the
device. Although skull immaturity may be considered a relative
contraindication in very young patients, this must be determined
on a case-by-case basis, given the variability in skull growth
and skull thickness in individual patients (eg, 4-mm thickness
of the skull at the site of RNS implant in our 3-yr-old patient).
Variable skull thickness can be assessed with use of computed
tomography (CT) scans routinely obtained as part of presurgical workups (eg, scans used to localize intracranial electrodes;
positron emission tomography). Given the smaller head size
and potentially thinner scalp, it is more critical to optimize the
positioning of the device to best fit the contour of the skull thus
minimizing the risk of skin breakdown in young children (usually
parietal area). The postoperative CT and skull X-rays in our 3-yrold patient (Figure 2) demonstrate that the RNS device can be
placed appropriately along the contour of the skull in a young
patient. Slightly larger craniectomy could be considered for the
device to accommodate a growing skull. Long-term follow-up of
these patients who had RNS implantation at a very young age will
be particularly important to evaluate the use of the RNS system
in the pediatric population.
With the establishment of open-loop deep brain stimulation
targeting the anterior nucleus of the thalamus,12 as well as closedloop RNS, the role of neuromodulation in treatment of epilepsy
has been expanding. However, their FDA-approved indication is
limited to adult patients. Given the diversity and complexity of
pediatric epilepsy, neuromodulation will likely play a significant
role in this population. Therefore, it is important to further investigate the effectiveness and safety of these devices and establish
the roles of these options in pediatric epilepsy in a randomized
multicenter study. The current study represents an important
first step towards the investigation of neuromodulation in the
pediatric population.

